➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Harvard Business School

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Adalimumab - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for adalimumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Hospital San Carlos, MadridPhase 3
Ministry for Health and Solidarity, FrancePhase 3
Shandong Qilu Stem Cells Engineering Co., Ltd.N/A

See all adalimumab clinical trials

Recent Litigation for adalimumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Pharmacyclics LLC v. Alvogen Pine Brook, LLC2020-03-20
Coherus Biosciences, Inc. v. Amgen Inc.2019-01-23
ABBVIE INC. v. SANDOZ INC.2018-08-10

See all adalimumab litigation

PTAB Litigation
PetitionerDate
Fresenius Kabi USA, LLC2019-09-17
2017-12-20
Sandoz Inc.2017-11-06

See all adalimumab litigation

Pharmacology for adalimumab

Patent Text Search: US Patents for adalimumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for adalimumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
04C/002 Belgium   Get Started Free PRODUCT NAME: ADALIMUMAB; AUTHORISATION NUMBER AND DATE: 56221 20030902
17/056 Ireland   Get Started Free PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
2016 00031 Denmark   Get Started Free PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
/2017 Austria   Get Started Free PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945/001-002 IDF DER FASSUNG DER ENTSCHEIDUNG DER KOMMISSION C(2015)4704 (MITTEILUNG) 20150707
C00050 Luxembourg   Get Started Free PRODUCT NAME: SARILUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (KEVZARA); AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
3 5006-2015 Slovakia   Get Started Free PRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023
2016 00056 Denmark   Get Started Free PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2016)3293 20160530
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Moodys
Mallinckrodt
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.